Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
Authors
Keywords
Thymidine conjugate, Thymidine phosphorylase, Thymidine kinase 1, Anticancer selectivity, Liver cancer
Journal
BMC CANCER
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-03-20
DOI
10.1186/s12885-015-1149-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Limits of [18F]-FLT PET as a Biomarker of Proliferation in Oncology
- (2013) Eliot T. McKinley et al. PLoS One
- Cyanine 5.5 Conjugated Nanobubbles as a Tumor Selective Contrast Agent for Dual Ultrasound-Fluorescence Imaging in a Mouse Model
- (2013) Liyi Mai et al. PLoS One
- Making Capecitabine Targeted Therapy for Breast Cancer: Which is the Role of Thymidine Phosphorylase?
- (2012) Marta Bonotto et al. Clinical Breast Cancer
- Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
- (2012) Eva-Maria Priego et al. CURRENT PHARMACEUTICAL DESIGN
- Radiolabeled Cyclosaligenyl Monophosphates of 5-Iodo-2′-deoxyuridine, 5-Iodo-3′-fluoro-2′,3′-dideoxyuridine, and 3′-Fluorothymidine for Molecular Radiotherapy of Cancer: Synthesis and Biological Evaluation
- (2012) Zbigniew P. Kortylewicz et al. JOURNAL OF MEDICINAL CHEMISTRY
- TAS-102 in refractory colorectal cancer: caution is needed
- (2012) Alberto Sobrero LANCET ONCOLOGY
- TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
- (2012) Takayuki Yoshino et al. LANCET ONCOLOGY
- Design, Synthesis, and In Vitro and In Vivo Biological Studies of a 3′-Deoxythymidine Conjugate that Potentially Kills Cancer Cells Selectively
- (2012) Qiong Wei et al. PLoS One
- Thymidine Kinase 1 Upregulation Is an Early Event in Breast Tumor Formation
- (2012) Melissa M. Alegre et al. Journal of Oncology
- The Kinetic Effects on Thymidine Kinase 2 by Enzyme-Bound dTTP May Explain the Mitochondrial Side Effects of Antiviral Thymidine Analogs
- (2011) Liya Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma
- (2011) Weijing Sun et al. CANCER
- DNA Alkylation withN-Methylquinolinium Quinone Methide toN2-dG Adducts Resulting in Extensive Stops in Primer Extension with DNA Polymerases and Subsequent Suppression of GFP Expression in A549 Cells
- (2011) Qibing Zhou et al. CHEMICAL RESEARCH IN TOXICOLOGY
- [18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells
- (2011) Cathy C. Zhang et al. CLINICAL CANCER RESEARCH
- High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma
- (2011) Yan Xu et al. TUMOR BIOLOGY
- A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma
- (2010) B Sangro et al. CANCER GENE THERAPY
- Antiangiogenic and Antitumor Activity of 6-(2-Aminoethyl)Amino-5-Chlorouracil, a Novel Small-Molecule Inhibitor of Thymidine Phosphorylase, in Combination with the Vascular Endothelial Growth Factor-Trap
- (2009) H. Lu et al. CLINICAL CANCER RESEARCH
- Thymidine Kinase 1 and Thymidine Phosphorylase Expression in Non-Small-cell Lung Carcinoma in Relation to Angiogenesis and Proliferation
- (2009) J. Scott Brockenbrough et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Nonpolar Nucleoside Mimics as Active Substrates for Human Thymidine Kinases
- (2009) Sarah K. Jarchow-Choy et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The dual role of thymidine phosphorylase in cancer development and chemotherapy
- (2009) Annelies Bronckaers et al. MEDICINAL RESEARCH REVIEWS
- Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors
- (2008) Michael J. Overman et al. CANCER INVESTIGATION
- Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
- (2008) Michael J. Overman et al. INVESTIGATIONAL NEW DRUGS
- Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors
- (2008) R. F. Barth et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More